{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T10:23:21Z","timestamp":1788085401786,"version":"build-2803163510"},"reference-count":109,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"unspecified","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Radiotheranostics is reshaping precision oncology by integrating molecular imaging with targeted radionuclide therapy through matched diagnostic\u2013therapeutic radiopharmaceutical pairs. Landmark clinical successes, including Lutetium-177-DOTATATE (\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE) and\n                    <jats:sup>177<\/jats:sup>\n                    Lu-prostate-specific membrane antigen-617 (\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA-617), have validated this approach and accelerated the shift from empiric dosing towards evidence-based practice supported by randomised trials. Beyond established somatostatin receptor and PSMA paradigms, emerging platforms targeting tumour\u2013stroma and lineage-associated biology, such as fibroblast activation protein and other receptor systems, are broadening applications across diverse malignancies. In parallel, advances in radionuclide science, including next-generation \u03b2-emitters and targeted \u03b1-particle therapies, are enabling strategies with higher biological effectiveness and potential advantages in small-volume and micrometastatic disease. Innovations in ligand and vector engineering (including half-life extension and multivalent constructs) aim to improve tumour retention and therapeutic index. Finally, quantitative imaging, personalised dosimetry (from organ-based to voxel-level approaches) and artificial intelligence (AI)-enabled workflows are laying the foundation for scalable, individualised treatment planning and response assessment. This review synthesises key developments in molecular targeting, radiochemistry, dosimetry, AI and combination strategies, outlining the priorities required to translate next-generation radiotheranostics into durable, multidisciplinary cancer care.\n                  <\/jats:p>","DOI":"10.1136\/bmjonc-2026-001073","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:25:25Z","timestamp":1783517125000},"page":"e001073","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Future of radiotheranostics"],"prefix":"10.1136","volume":"5","clinical-trial-number":[{"clinical-trial-number":"nct06375564","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05521412","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04868604","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05896371","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04720157","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04919226","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05521412","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06780670","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05636618","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06356922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06955169","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06590857","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06939036","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04939610","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06710756","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07156565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06305962","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06824155","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06184035","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06496581","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06320067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05939414","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05204927","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04720157","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04689828","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04647526","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04876651","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00859781","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06780670","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07208240","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05387603","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04919226","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03049189","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04261855","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06955169","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07150806","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06590857","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05636618","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06132737","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05239533","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04743661","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"},{"name":"The University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serin","family":"Moghrabi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad Mohammad","family":"Al-Houwari","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soud","family":"Al-Qasem","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwah","family":"Abdulrahman","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouraldeen","family":"Alzorgan","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louai","family":"Sohil Al-Qatawna","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5177-3371","authenticated-orcid":false,"given":"Qais","family":"Al-Hammouri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jordanian Royal Medical Services, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghanameh","sequence":"additional","affiliation":[{"name":"School of Medicine, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ruzzeh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Saad","family":"Abdlkadir","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, King Hussein Cancer Center, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026070806251811000_5.2.e001073.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Sig Transduct Target Ther"},{"key":"2026070806251811000_5.2.e001073.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06255-8"},{"key":"2026070806251811000_5.2.e001073.3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/COC.0000000000000903","article-title":"ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy","volume":"45","author":"Love","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"2026070806251811000_5.2.e001073.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30821-6"},{"key":"2026070806251811000_5.2.e001073.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2330-6"},{"key":"2026070806251811000_5.2.e001073.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2026070806251811000_5.2.e001073.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2026070806251811000_5.2.e001073.8","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2025.1655419","article-title":"Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade","volume":"5","author":"Haugh","year":"2025","journal-title":"Front Nucl Med"},{"key":"2026070806251811000_5.2.e001073.9","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a Lancet Oncology Commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026070806251811000_5.2.e001073.10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/tomography11080083","article-title":"Emerging PET Imaging Agents and Targeted Radioligand Therapy: A Review of Clinical Applications and Trials","volume":"11","author":"Palihati","year":"2025","journal-title":"Tomography"},{"key":"2026070806251811000_5.2.e001073.11","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study","volume":"29","author":"Fu","year":"2023","journal-title":"Clinical Cancer Research"},{"key":"2026070806251811000_5.2.e001073.12","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A , Abdlkadir AS , Ruzzeh S , et al . [177Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review. Semin Nucl Med 2025. doi:10.1053\/j.semnuclmed.2025.06.010","DOI":"10.1053\/j.semnuclmed.2025.06.010"},{"key":"2026070806251811000_5.2.e001073.13","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: A systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"key":"2026070806251811000_5.2.e001073.14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13139-025-00936-y","article-title":"Exploring the Diagnostic and Theranostic Role of FAPI PET in Soft Tissue Sarcoma: A Systematic Review","volume":"59","author":"Abdulrahman","year":"2025","journal-title":"Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.15","first-page":"251921","article-title":"A retrospective analysis of safety, efficacy and survival of metastatic colorectal cancer patients treated with actinium-225 FAP-directed radiopharmaceutical therapy","volume":"66","author":"Perrone","year":"2025","journal-title":"J Nucl Med"},{"key":"2026070806251811000_5.2.e001073.16","doi-asserted-by":"publisher","DOI":"10.7150\/thno.4835"},{"key":"2026070806251811000_5.2.e001073.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235920","article-title":"In Vivo Targeting of CXCR4-New Horizons","volume":"13","author":"Schottelius","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026070806251811000_5.2.e001073.18","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/JLB.5BT1219-714R","article-title":"At the Bedside: Profiling and treating patients with CXCR4-expressing cancers","volume":"109","author":"Martin","year":"2021","journal-title":"J Leukoc Biol"},{"key":"2026070806251811000_5.2.e001073.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.167361"},{"key":"2026070806251811000_5.2.e001073.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.210997"},{"key":"2026070806251811000_5.2.e001073.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264207"},{"key":"2026070806251811000_5.2.e001073.22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7150\/thno.101215","article-title":"CXCR4-directed endoradiotherapy with [177Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Braitsch","year":"2025","journal-title":"Theranostics"},{"key":"2026070806251811000_5.2.e001073.23","doi-asserted-by":"crossref","DOI":"10.1002\/cbic.202500676","article-title":"Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management","volume":"27","author":"Shaikh","year":"2026","journal-title":"Chembiochem"},{"key":"2026070806251811000_5.2.e001073.24","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263323"},{"key":"2026070806251811000_5.2.e001073.25","first-page":"481","article-title":"Preclinical Evaluation of Gastrin-Releasing Peptide Receptor Antagonists Labeled with 161Tb and 177Lu: A Comparative Study","volume":"65","author":"Holzleitner","year":"2024","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"2026070806251811000_5.2.e001073.26","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178889"},{"key":"2026070806251811000_5.2.e001073.27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B"},{"key":"2026070806251811000_5.2.e001073.28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.016"},{"key":"2026070806251811000_5.2.e001073.30","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17070912","article-title":"Nanoradiopharmaceuticals: Design Principles, Radiolabeling Strategies, and Biomedicine Applications","volume":"17","author":"N\u00fa\u00f1ez-Salinas","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026070806251811000_5.2.e001073.31","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","article-title":"Phase I Trial of 131I-GMIB-Anti-HER2-VHH1, a New Promising Candidate for HER2-Targeted Radionuclide Therapy in Breast Cancer Patients","volume":"62","author":"D\u2019Huyvetter","year":"2021","journal-title":"J Nucl Med"},{"key":"2026070806251811000_5.2.e001073.32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213412","article-title":"Radioligand Therapy in Cancer Management: A Global Perspective","volume":"17","author":"Ninatti","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026070806251811000_5.2.e001073.33","doi-asserted-by":"publisher","DOI":"10.7150\/thno.39203"},{"key":"2026070806251811000_5.2.e001073.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026070806251811000_5.2.e001073.35","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","article-title":"68Ga-DOTA-RGD2 Positron Emission Tomography\/Computed Tomography in Radioiodine Refractory Thyroid Cancer: Prospective Comparison of Diagnostic Accuracy with 18F-FDG Positron Emission Tomography\/Computed Tomography and Evaluation Toward Potential Theranostics","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"key":"2026070806251811000_5.2.e001073.36","doi-asserted-by":"crossref","first-page":"102940","DOI":"10.1016\/j.ctrv.2025.102940","article-title":"Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology","volume":"136","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"2026070806251811000_5.2.e001073.37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215570","article-title":"Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials","volume":"13","author":"Rondon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026070806251811000_5.2.e001073.38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/ijnm.ijnm_87_25","article-title":"Is Terbium-161 the Next Lutetium-177? A New Era for Theranostics on the Horizon","volume":"40","author":"Sharma","year":"2025","journal-title":"Indian J Nucl Med"},{"key":"2026070806251811000_5.2.e001073.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00332-8"},{"key":"2026070806251811000_5.2.e001073.40","doi-asserted-by":"crossref","DOI":"10.3390\/ph17010076","article-title":"Alpha-Emitting Radionuclides: Current Status and Future Perspectives","volume":"17","author":"Miederer","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026070806251811000_5.2.e001073.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.143842"},{"key":"2026070806251811000_5.2.e001073.42","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263230"},{"key":"2026070806251811000_5.2.e001073.43","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00652-y"},{"key":"2026070806251811000_5.2.e001073.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2026070806251811000_5.2.e001073.45","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266125"},{"key":"2026070806251811000_5.2.e001073.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"2026070806251811000_5.2.e001073.47","doi-asserted-by":"crossref","first-page":"1076210","DOI":"10.3389\/fmed.2022.1076210","article-title":"Astatine-211 based radionuclide therapy: Current clinical trial landscape","volume":"9","author":"Albertsson","year":"2022","journal-title":"Front Med"},{"key":"2026070806251811000_5.2.e001073.48","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","article-title":"Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab","volume":"28","author":"Rosenblat","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"2026070806251811000_5.2.e001073.49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0382"},{"key":"2026070806251811000_5.2.e001073.50","first-page":"672","article-title":"227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed\/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study","volume":"36","author":"Lind\u00e9n","year":"2021","journal-title":"Cancer Biother Radiopharm"},{"key":"2026070806251811000_5.2.e001073.51","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1007\/s00259-025-07168-4","article-title":"Evaluating Xerostomia as a side effect of [255Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis","volume":"52","author":"Al-Ibraheem","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.52","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.53","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-022-05766-0","article-title":"Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond","volume":"49","author":"Younis","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.54","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s13139-023-00814-5","article-title":"[177Lu]Lu-DOTAGA.Glu.(FAPi)2 Radionuclide Therapy: a New Treatment Option for Patients with Glioblastoma Multiforme","volume":"58","author":"Ballal","year":"2024","journal-title":"Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.55","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"key":"2026070806251811000_5.2.e001073.56","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111567","article-title":"Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models","volume":"25","author":"Abe","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026070806251811000_5.2.e001073.57","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.semradonc.2023.03.011","article-title":"Theranostics and Patient-Specific Dosimetry","volume":"33","author":"Bednarz","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"2026070806251811000_5.2.e001073.58","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262977"},{"key":"2026070806251811000_5.2.e001073.59","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262754"},{"key":"2026070806251811000_5.2.e001073.60","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1355912","article-title":"Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium","volume":"4","author":"Ramonaheng","year":"2024","journal-title":"Front Nucl Med"},{"key":"2026070806251811000_5.2.e001073.61","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265448"},{"key":"2026070806251811000_5.2.e001073.62","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264953"},{"key":"2026070806251811000_5.2.e001073.63","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2026070806251811000_5.2.e001073.64","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2023.1291253","article-title":"Quantitative imaging for 177Lu-PSMA treatment response monitoring and dosimetry","volume":"3","author":"Meyer","year":"2023","journal-title":"Front Nucl Med"},{"key":"2026070806251811000_5.2.e001073.65","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.267452"},{"key":"2026070806251811000_5.2.e001073.66","article-title":"A Phase I\/II Study of [177 Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol","volume":"66","author":"Harsini","year":"2025","journal-title":"J Nucl Med"},{"key":"2026070806251811000_5.2.e001073.67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00259-023-06420-z","article-title":"Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs","volume":"51","author":"Bodei","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.68","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2967\/jnumed.117.201095","article-title":"Whole-Body Voxel-Based Personalized Dosimetry: The Multiple Voxel S-Value Approach for Heterogeneous Media with Nonuniform Activity Distributions","volume":"59","author":"Lee","year":"2018","journal-title":"J Nucl Med"},{"key":"2026070806251811000_5.2.e001073.69","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264594"},{"key":"2026070806251811000_5.2.e001073.70","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-023-00952-z","article-title":"Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation","volume":"13","author":"Peters","year":"2023","journal-title":"EJNMMI Res"},{"key":"2026070806251811000_5.2.e001073.71","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.123.267067"},{"key":"2026070806251811000_5.2.e001073.72","doi-asserted-by":"crossref","DOI":"10.1186\/s41824-023-00172-7","article-title":"AI-based quantification of whole-body tumour burden on somatostatin receptor PET\/CT","volume":"7","author":"G\u00e5lne","year":"2023","journal-title":"Eur J Hybrid Imaging"},{"key":"2026070806251811000_5.2.e001073.73","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.7150\/thno.94788","article-title":"Theranostics and artificial intelligence: new frontiers in personalized medicine","volume":"14","author":"Belge Bilgin","year":"2024","journal-title":"Theranostics"},{"key":"2026070806251811000_5.2.e001073.74","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11307-022-01775-5","article-title":"Manual Versus Artificial Intelligence-Based Segmentations as a Pre-processing Step in Whole-body PET Dosimetry Calculations","volume":"25","author":"van Sluis","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"2026070806251811000_5.2.e001073.75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13139-025-00939-9","article-title":"The Role of Artificial Intelligence in Advancing Theranostics Dosimetry for Cancer Therapy: a Review","volume":"59","author":"Woo","year":"2025","journal-title":"Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.76","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2023.1234853","article-title":"Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"3","author":"Gutsche","year":"2023","journal-title":"Front Nucl Med"},{"key":"2026070806251811000_5.2.e001073.77","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ijrobp.2017.12.268","article-title":"Challenges and Promises of PET Radiomics","volume":"102","author":"Cook","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026070806251811000_5.2.e001073.78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153835","article-title":"A Multicentre Evaluation of Dosiomics Features Reproducibility, Stability and Sensitivity","volume":"13","author":"Placidi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026070806251811000_5.2.e001073.79","doi-asserted-by":"crossref","DOI":"10.4103\/jmss.jmss_54_23","article-title":"Predicting the Response of Patients Treated with 177Lu-DOTATATE Using Single-photon Emission Computed Tomography-Computed Tomography Image-based Radiomics and Clinical Features","volume":"14","author":"Behmanesh","year":"2024","journal-title":"J Med Signals Sens"},{"key":"2026070806251811000_5.2.e001073.80","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3390\/cancers18081194","article-title":"Multimodal Deep Learning for Prediction of Progression-Free Survival in Patients with Neuroendocrine Tumors Undergoing 177Lu-Based Peptide Receptor Radionuclide Therapy","volume":"18","author":"Baur","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026070806251811000_5.2.e001073.81","doi-asserted-by":"crossref","DOI":"10.3390\/jpm14111068","article-title":"Predicting Response to [177Lu]Lu-PSMA Therapy in mCRPC Using Machine Learning","volume":"14","author":"Gong","year":"2024","journal-title":"J Pers Med"},{"key":"2026070806251811000_5.2.e001073.82","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"2026070806251811000_5.2.e001073.83","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1331364","article-title":"Immunological effects of radiopharmaceutical therapy","volume":"4","author":"Shea","year":"2024","journal-title":"Front Nucl Med"},{"key":"2026070806251811000_5.2.e001073.84","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026070806251811000_5.2.e001073.85","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13271"},{"key":"2026070806251811000_5.2.e001073.86","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17223717","article-title":"PSMA Theranostics in Prostate Cancer and Beyond: Current and Future Perspectives","volume":"17","author":"Sandhu","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026070806251811000_5.2.e001073.87","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","author":"Kim","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026070806251811000_5.2.e001073.88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"2026070806251811000_5.2.e001073.89","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00529-6"},{"key":"2026070806251811000_5.2.e001073.90","unstructured":"US Food and Drug Administration . FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. FDA; 2025. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication [Accessed 06 Feb 2026]."},{"key":"2026070806251811000_5.2.e001073.91","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1007\/s00259-025-07246-7","article-title":"Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study","volume":"52","author":"Gaze","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.92","unstructured":"US Food and Drug Administration . FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS. 2024. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lutetium-lu-177-dotatate-pediatric-patients-12-years-and-older-gep-nets [Accessed 06 Feb 2026]."},{"key":"2026070806251811000_5.2.e001073.93","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1200\/JCO-25-01553","article-title":"177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study","volume":"43","author":"Kishan","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026070806251811000_5.2.e001073.94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026070806251811000_5.2.e001073.95","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00440-6"},{"key":"2026070806251811000_5.2.e001073.96","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"2026070806251811000_5.2.e001073.97","unstructured":"eCFR:: Home. Available: https:\/\/www.ecfr.gov\/ [Accessed 6 Feb 2026]."},{"key":"2026070806251811000_5.2.e001073.98","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1007\/s00259-024-06640-x","article-title":"EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials","volume":"51","author":"Stokke","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026070806251811000_5.2.e001073.99","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269215"},{"key":"2026070806251811000_5.2.e001073.100","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264321"},{"key":"2026070806251811000_5.2.e001073.101","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026070806251811000_5.2.e001073.102","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","article-title":"Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics","volume":"25","author":"Scott","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026070806251811000_5.2.e001073.103","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(22)00138-3","article-title":"Rays of Hope: the IAEA ups its commitment to cancer care","volume":"23","author":"Grossi","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026070806251811000_5.2.e001073.104","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A , Brink A , Lee ST , et al . Implementation of Radiotheranostics: Challenges, Barriers, and IAEA-Driven Strategies for Sustainable Access. Semin Nucl Med 2025. doi:10.1053\/j.semnuclmed.2025.07.005","DOI":"10.1053\/j.semnuclmed.2025.07.005"},{"key":"2026070806251811000_5.2.e001073.105","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A . Worldwide Potential of Radiotheranostics and the Challenges Faced by Developing Countries. J Nucl Med 2025. doi:10.2967\/jnumed.125.271249","DOI":"10.2967\/jnumed.125.271249"},{"key":"2026070806251811000_5.2.e001073.106","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.247197"},{"key":"2026070806251811000_5.2.e001073.107","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.261016"},{"key":"2026070806251811000_5.2.e001073.108","doi-asserted-by":"crossref","first-page":"109008","DOI":"10.1016\/j.nucmedbio.2025.109008","article-title":"IAEA activities to support the member states in the production of targeted alpha therapy radiopharmaceuticals","volume":"144\u2013145","author":"Jalilian","year":"2025","journal-title":"Nucl Med Biol"},{"key":"2026070806251811000_5.2.e001073.109","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.semnuclmed.2024.02.003","article-title":"Radiotheranostics Global Market and Future Developments","volume":"54","author":"Al-Ibraheem","year":"2024","journal-title":"Semin Nucl Med"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2026-001073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T13:25:34Z","timestamp":1783517134000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2026-001073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":109,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjonc-2026-001073"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2026-001073","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}